AdvertisementSupported byBy The Associated PressStocks rose on Thursday as the price of oil climbed for the third day in a row while key oil-producing nations like Russia and Saudi Arabia discussed cuts in production. Technology and consumer stocks traded higher while drug makers fell.Facebook made its biggest leap in two and a half years. On Wednesday, it reported that its profit more than doubled in the fourth quarter. Facebook finished 2015 with almost 1.6 billion users. The sports apparel maker Under Armour also surged. The Dow Jones industrial average climbed 125.18 points, or 0.8 percent, to 16,069.64. The Standard & Poor’s 500-stock index picked up 10.41 points, or 0.6 percent, to 1,893.36. The Nasdaq composite index rose 38.51 points, or 0.9 percent, to 4,506.68.Stocks switched between small gains and losses throughout the morning. In the afternoon, they gradually traded higher, but never went as high as they had reached at the very beginning of the day.United States crude rose 92 cents, or 2.8 percent, to $33.22 a barrel in New York. Brent crude, a benchmark for international oils, gained 79 cents, or 2.4 percent, to $33.89. The price of United States oil has climbed 9.5 percent over the last three days as investors hope production will be reduced, which would strengthen the fuel’s price.The oil and natural gas producer Devon Energy rose $2.30, or 9.4 percent, to $26.79. The oil company Hess, which rose almost 6 percent on Wednesday after it had said it will cut more spending, picked up $3.49, or 9.5 percent, to $40.34.Facebook said it gained 46 million users, giving it 1.59 billion users around the world. Its stock rose $14.66, or 15.5 percent, to $109.11, its best day since July 2013.Under Armour reported a larger-than-expected profit and better revenue than analysts had forecast. The company said shoe revenue almost doubled on strong sales of Stephen Curry basketball sneakers. Its stock climbed $15.49, or 22.6 percent, to $84.07, for its biggest one-day gain in two years.Drug stocks tumbled, and the biggest losses went to companies that make complex, costly drugs. The shares of the cancer drug maker Celgene lost $5.10, or 5 percent, to $97.21 after its 2016 estimates disappointed investors.The Massachusetts attorney general’s office said on Wednesday it was investigating whether the high price of a new hepatitis C drug from another biotech firm, Gilead Sciences, violates state law. Gilead shares fell $2.10, or 2.3 percent, to $87.53.Biotech stocks have fallen in recent months as controversy over drug prices has increased. The Nasdaq biotech index fell 3.5 percent on Thursday. That index hit a record high in July and has lost about a third of its value since then.Abbott Laboratories shares lost $3.76, or 9.3 percent, to $36.71 after the maker of infant formula, medical devices and drugs posted quarterly profits that disappointed investors.Bond prices rose. The yield on the 10-year Treasury note slipped to 1.98 percent from 2 percent. The euro rose to $1.0938 from $1.0891. The dollar rose to 118.80 yen from 118.60 yen.Advertisement